Subscribe to our Email Alerts

Coverage


 
    Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial  
 
    Amplia Therapeutics receives $1.8 million R&D refund for cancer inhibitor studies  
 
    Amplia Therapeutics achieves critical clinical milestone for lead cancer therapy  
 
    Amplia Therapeutics says Garvan paper has increased its confidence in upcoming Phase 2 trial  
 
    Amplia Therapeutics and Patrys outline unique cancer drugs at Proactive Lifesciences Webinar  
 
    Amplia Therapeutics develops new approach to treat cancer and fibrosis  
 
    Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis  
 
    Amplia Therapeutics returns successful phase one trial results  
 
    Garvan's June Seminar: The Power of Personalised Medicine  
 
    Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug  
 
    Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment  
 
    Positive data sends Amplia Therapeutics nearly 50 per cent up  
 
    Amplia Therapeutics (ASX:ATX) signs agreement with Garvan Institute  
 
    Amplia Therapeutics (ASX:ATX) completes single-dose study of AMP945  
 
    Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release  
 
    Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone  
 
    Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone